Prestige Consumer Healthcare Future Growth
Future criteria checks 1/6
Prestige Consumer Healthcare is forecast to grow earnings and revenue by 5.3% and 2.4% per annum respectively. EPS is expected to grow by 6% per annum. Return on equity is forecast to be 10.8% in 3 years.
Key information
5.3%
Earnings growth rate
6.0%
EPS growth rate
| Pharmaceuticals earnings growth | 23.8% |
| Revenue growth rate | 2.4% |
| Future return on equity | 10.8% |
| Analyst coverage | Good |
| Last updated | 08 Nov 2024 |
Recent future growth updates
Recent updates
We Think Prestige Consumer Healthcare (NYSE:PBH) Can Stay On Top Of Its Debt
Nov 03
Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Popularity With Investors Is Under Threat From Overpricing
Sep 10Prestige Consumer Healthcare (NYSE:PBH) Seems To Use Debt Quite Sensibly
Jul 16Revenues Not Telling The Story For Prestige Consumer Healthcare Inc. (NYSE:PBH)
May 22Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Mar 26An Intrinsic Calculation For Prestige Consumer Healthcare Inc. (NYSE:PBH) Suggests It's 50% Undervalued
Mar 05Prestige Consumer Healthcare Inc. (NYSE:PBH) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Feb 11Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Shares May Have Run Too Fast Too Soon
Feb 05Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Dec 14Prestige Consumer Healthcare (NYSE:PBH) Seems To Use Debt Quite Sensibly
Sep 10Prestige Consumer Healthcare: Unproductive Buyback And Excessive Valuation
Aug 15Is Prestige Consumer Healthcare (NYSE:PBH) Using Too Much Debt?
Jun 12An Intrinsic Calculation For Prestige Consumer Healthcare Inc. (NYSE:PBH) Suggests It's 43% Undervalued
May 20Here's Why Prestige Consumer Healthcare (NYSE:PBH) Has Caught The Eye Of Investors
Mar 17Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Mar 02Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Intrinsic Value Is Potentially 75% Above Its Share Price
Feb 08Prestige Consumer Healthcare reports Q3 earnings beat; updates FY23 guidance
Feb 02Prestige Consumer Healthcare: Taking My Winnings Off The Table
Jan 19Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Nov 23Prestige Consumer Healthcare GAAP EPS of $1.02 beats by $0.02, revenue of $289.3M beats by $6.07M
Nov 03Holding Prestige Consumer Healthcare
Aug 31If EPS Growth Is Important To You, Prestige Consumer Healthcare (NYSE:PBH) Presents An Opportunity
Aug 26We Think Prestige Consumer Healthcare (NYSE:PBH) Can Stay On Top Of Its Debt
Aug 05Prestige Consumer Healthcare GAAP EPS of $1.09 beats by $0.05, revenue of $277.1M beats by $8.18M
Aug 04Should You Be Adding Prestige Consumer Healthcare (NYSE:PBH) To Your Watchlist Today?
May 27Is Prestige Consumer Healthcare (NYSE:PBH) A Risky Investment?
May 05Does Prestige Consumer Healthcare (NYSE:PBH) Deserve A Spot On Your Watchlist?
Feb 22Is Prestige Consumer Healthcare (NYSE:PBH) A Risky Investment?
Feb 03These 4 Measures Indicate That Prestige Consumer Healthcare (NYSE:PBH) Is Using Debt Extensively
Nov 04Here's Why Prestige Consumer Healthcare (NYSE:PBH) Has A Meaningful Debt Burden
Aug 06Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2027 | 1,182 | 242 | 271 | 288 | 3 |
| 3/31/2026 | 1,159 | 238 | 271 | 287 | 8 |
| 3/31/2025 | 1,132 | 224 | 256 | 271 | 8 |
| 9/30/2024 | 1,111 | 206 | 255 | 263 | N/A |
| 6/30/2024 | 1,113 | 205 | 246 | 256 | N/A |
| 3/31/2024 | 1,125 | 209 | 239 | 249 | N/A |
| 12/31/2023 | 1,134 | -81 | 232 | 241 | N/A |
| 9/30/2023 | 1,127 | -82 | 216 | 224 | N/A |
| 6/30/2023 | 1,130 | -84 | 211 | 220 | N/A |
| 3/31/2023 | 1,128 | -82 | 222 | 230 | N/A |
| 12/31/2022 | 1,109 | 210 | 225 | 234 | N/A |
| 9/30/2022 | 1,108 | 209 | 236 | 245 | N/A |
| 6/30/2022 | 1,095 | 203 | 240 | 249 | N/A |
| 3/31/2022 | 1,087 | 205 | 250 | 260 | N/A |
| 12/31/2021 | 1,058 | 189 | 245 | 256 | N/A |
| 9/30/2021 | 1,022 | 179 | 224 | 239 | N/A |
| 6/30/2021 | 983 | 179 | 209 | 230 | N/A |
| 3/31/2021 | 943 | 165 | 213 | 236 | N/A |
| 12/31/2020 | 957 | 166 | 207 | 233 | N/A |
| 9/30/2020 | 960 | 163 | 218 | 241 | N/A |
| 6/30/2020 | 960 | 152 | 222 | 240 | N/A |
| 3/31/2020 | 963 | 142 | 203 | 217 | N/A |
| 12/31/2019 | 953 | -34 | 199 | 212 | N/A |
| 9/30/2019 | 953 | -34 | 186 | 197 | N/A |
| 6/30/2019 | 954 | -36 | 176 | 186 | N/A |
| 3/31/2019 | 976 | -36 | 179 | 189 | N/A |
| 12/31/2018 | 991 | 64 | 183 | 193 | N/A |
| 9/30/2018 | 1,020 | 340 | 184 | 197 | N/A |
| 6/30/2018 | 1,039 | 340 | N/A | 212 | N/A |
| 3/31/2018 | 1,041 | 340 | N/A | 210 | N/A |
| 12/31/2017 | 1,026 | 390 | N/A | 163 | N/A |
| 9/30/2017 | 972 | 107 | N/A | 156 | N/A |
| 6/30/2017 | 929 | 109 | N/A | 151 | N/A |
| 3/31/2017 | 882 | 69 | N/A | 149 | N/A |
| 12/31/2016 | 849 | 72 | N/A | 179 | N/A |
| 9/30/2016 | 833 | 69 | N/A | 185 | N/A |
| 6/30/2016 | 824 | 68 | N/A | 182 | N/A |
| 3/31/2016 | 806 | 100 | N/A | 176 | N/A |
| 12/31/2015 | 788 | 110 | N/A | 189 | N/A |
| 9/30/2015 | 786 | 103 | N/A | 190 | N/A |
| 6/30/2015 | 761 | 88 | N/A | 170 | N/A |
| 3/31/2015 | 715 | 78 | N/A | 156 | N/A |
| 12/31/2014 | 668 | 70 | N/A | 135 | N/A |
| 9/30/2014 | 615 | 52 | N/A | 113 | N/A |
| 6/30/2014 | 601 | 69 | N/A | 118 | N/A |
| 3/31/2014 | 597 | 73 | N/A | 112 | N/A |
| 12/31/2013 | 609 | 76 | N/A | 118 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PBH's forecast earnings growth (5.3% per year) is above the savings rate (2.6%).
Earnings vs Market: PBH's earnings (5.3% per year) are forecast to grow slower than the US market (15.3% per year).
High Growth Earnings: PBH's earnings are forecast to grow, but not significantly.
Revenue vs Market: PBH's revenue (2.4% per year) is forecast to grow slower than the US market (8.9% per year).
High Growth Revenue: PBH's revenue (2.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PBH's Return on Equity is forecast to be low in 3 years time (10.8%).